ANNEXON, INC. Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount
ANNEXON, INC. (ANNX) had Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount of $0 as of 2020-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount · last filed 2020-11-16
- 2020-09-30: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2019-12-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-11-16 |
| 2019-12-31 | $0.00 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |